Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2029772 | 0.86 | CYP3A4 (0.78) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| SCHEMBL31335763 | 0.85 | CYP3A4 (0.51) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| Xanthoxylin SCHEMBL29349586 | 0.79 | CYP3A4 (1.00) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| Xanthoxylin SCHEMBL44708 | 0.79 | CYP3A4 (1.00) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| SCHEMBL16018016 | 0.79 | CYP3A4 (0.68) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| Xanthoxylin SCHEMBL28802531 | 0.78 | CYP3A4 (0.96) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| SCHEMBL2203125 | 0.78 | CYP3A4 (0.66) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| SCHEMBL12303218 | 0.76 | CYP3A4 (0.64) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| SCHEMBL5209995 | 0.76 | CYP3A4 (0.53) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| SCHEMBL23167800 | 0.75 | CYP3A4 (0.62) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10470986-B2 | Resorcinol compounds for dermatological use | CONOPCO, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10470986-B2 | Resorcinol compounds for dermatological use | CONOPCO, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| EP-2964182-B1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER PLC A COMPANY REGISTERED IN ENGLAND AND WALES UNDER COMPANY NO 41424 OF (GB) | 2018-02-14 | — | — | EP | disclosed |
| EP-2964182-B1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER PLC A COMPANY REGISTERED IN ENGLAND AND WALES UNDER COMPANY NO 41424 OF (GB) | 2018-02-14 | — | — | EP | disclosed |
| EP-2964182-A2 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | Unilever PLC, a company registered in England and Wales under company no. 41424 of (GB) | 2016-01-13 | — | — | EP | disclosed |
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | CONOPCO, INC., D/B/A UNILEVER (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | CONOPCO, INC., D/B/A UNILEVER (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | CONOPCO, INC., D/B/A UNILEVER (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2014138471-A2 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | AMPERE LIFE SCIENCES, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014138471-A2 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | AMPERE LIFE SCIENCES, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER N.V. (NL) | 2014-09-11 | — | — | US | disclosed |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER N.V. (NL) | 2014-09-11 | — | — | US | disclosed |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER N.V. (NL) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | NQO1, RBP4, KEAP1 | CYP3A4 1742/4885USP2 974/4885MAPK1 2819/4885 |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | NQO1, RBP4, KEAP1 | CYP3A4 1742/4885USP2 974/4885MAPK1 2819/4885 |
| US-10470986-B2 | Resorcinol compounds for dermatological use | NQO1, RBP4, KEAP1 | CYP3A4 1742/4885USP2 974/4885MAPK1 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.